Decreased risk of breast cancer associated with oral bisphosphonate therapy

Aju Mathew,1 Adam Brufsky,21Department of Internal Medicine, University of Pittsburgh Medical Center, 2Division of Hematology/Oncology, Magee-Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USAAbstract: Preclinical studies and adjuvant trials using bisphosphonates have fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mathew A, Brufsky A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7ba30ee2c0064d89a8d91a7226d0fe49
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7ba30ee2c0064d89a8d91a7226d0fe49
record_format	dspace
spelling	oai:doaj.org-article:7ba30ee2c0064d89a8d91a7226d0fe492021-12-02T08:24:48ZDecreased risk of breast cancer associated with oral bisphosphonate therapy1179-1314https://doaj.org/article/7ba30ee2c0064d89a8d91a7226d0fe492012-05-01T00:00:00Zhttp://www.dovepress.com/decreased-risk-of-breast-cancer-associated-with-oral-bisphosphonate-th-a9955https://doaj.org/toc/1179-1314Aju Mathew,1 Adam Brufsky,21Department of Internal Medicine, University of Pittsburgh Medical Center, 2Division of Hematology/Oncology, Magee-Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USAAbstract: Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their use has been fraught with significant adverse effects such as venous thromboembolic events and an increased risk for endometrial cancer. In this context, several recent observational studies have investigated a chemoprevention role for oral bisphosphonates in decreasing risk for breast cancer. This review will aim to summarize these studies and present a critical evaluation of the association between oral bisphosphonate use and breast cancer risk reduction.Keywords: incidence, risk reduction, chemoprophylaxis, alendronate, zoledronateMathew ABrufsky ADove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 75-81 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mathew A Brufsky A Decreased risk of breast cancer associated with oral bisphosphonate therapy
description	Aju Mathew,1 Adam Brufsky,21Department of Internal Medicine, University of Pittsburgh Medical Center, 2Division of Hematology/Oncology, Magee-Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USAAbstract: Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their use has been fraught with significant adverse effects such as venous thromboembolic events and an increased risk for endometrial cancer. In this context, several recent observational studies have investigated a chemoprevention role for oral bisphosphonates in decreasing risk for breast cancer. This review will aim to summarize these studies and present a critical evaluation of the association between oral bisphosphonate use and breast cancer risk reduction.Keywords: incidence, risk reduction, chemoprophylaxis, alendronate, zoledronate
format	article
author	Mathew A Brufsky A
author_facet	Mathew A Brufsky A
author_sort	Mathew A
title	Decreased risk of breast cancer associated with oral bisphosphonate therapy
title_short	Decreased risk of breast cancer associated with oral bisphosphonate therapy
title_full	Decreased risk of breast cancer associated with oral bisphosphonate therapy
title_fullStr	Decreased risk of breast cancer associated with oral bisphosphonate therapy
title_full_unstemmed	Decreased risk of breast cancer associated with oral bisphosphonate therapy
title_sort	decreased risk of breast cancer associated with oral bisphosphonate therapy
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/7ba30ee2c0064d89a8d91a7226d0fe49
work_keys_str_mv	AT mathewa decreasedriskofbreastcancerassociatedwithoralbisphosphonatetherapy AT brufskya decreasedriskofbreastcancerassociatedwithoralbisphosphonatetherapy
_version_	1718398551863590912

Decreased risk of breast cancer associated with oral bisphosphonate therapy

Ejemplares similares